EXPERIMENTAL DRUGS / POTENTIAL ANTIBIOTIC THERAPIES AGAINST M. ULCERANS
Rifampicin
CLASS
Rifamycin
TARGET PROTEIN
RNA synthesis through interfering with bacterial RNA-polymerase
MECHANISM OF ACTION
Bactericidal activity (act on mycobacteria by inhibiting RNA synthesis through interfering with bacterial RNA-polymerase)
DRUG INTERACTION PHASE (APPROVED, INVESTIGATIONAL, EXPERIMENTAL)
Approved
MODE OF ADMINISTRATION
Oral
LINK TO PUBMED
https://pubmed.ncbi.nlm.nih.gov/32091697/
https://pubmed.ncbi.nlm.nih.gov/24396561/
https://pubmed.ncbi.nlm.nih.gov/30136733/
SIMILAR TARGETS IN OTHER SPECIES
DNA-directed RNA polymerase subunit beta ~ Escherichia coli (strain K12)
DRUG BANK ID
DB01045
EXTERNAL LINKS
Human Metabolome Database HMDB15179
KEGG Drug D00211
KEGG Compound C06688
PubChem Compound 5381226
PubChem Substance 46506170
ChemSpider 10468813
BindingDB 50370232
RxNav 9384
ChEBI 71365
ChEMBL CHEMBL374478
ZINC ZINC000169621223
Guide to Pharmacology GtP Drug Page
Drugs.com Drugs.com Drug Page https://www.drugs.com/cdi/rifampin.htm
Wikipedia Rifampicin
REFERENCE
Vouking, M. Z., Tamo, V. C., & Tadenfok, C. N. (2013). Clinical efficacy of Rifampicin and Streptomycin in combination against Mycobacterium ulcerans infection: A systematic review. In Pan African Medical Journal (Vol. 15). Pan Afr Med J. https://doi.org/10.11604/pamj.2013.15.155.2341
Pluschke, G., & Röltgen, K. (2019). Buruli ulcer: Mycobacterium ulcerans disease. In Buruli Ulcer: Mycobacterium ulcerans Disease. https://doi.org/10.1007/978-3-030-11114-4
Yotsu, R. R., Richardson, M., & Ishii, N. (2018). Drugs for treating Buruli ulcer (Mycobacterium ulcerans disease). Cochrane Database of Systematic Reviews, 2018(8). https://doi.org/10.1002/14651858.CD012118.pub2
Organization, W. H. (2022). WHO Drug Study for Buruli Ulcer - Comparison of SR8 and CR8 - Full Text View - ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT01659437